{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:39:22Z","timestamp":1790127562025,"version":"4.0.1"},"reference-count":67,"publisher":"BMJ","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2011,6,15]]},"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p>Selective serotonin reuptake inhibitors (SSRIs) are increasingly used during pregnancy and lactation, with 1.8\u20132.8% exposed pregnancies. Given the risks of untreated maternal depression for both mother and child, adequate treatment is essential. If pharmacological treatment with SSRIs is indicated, the fetal and neonatal effects of SSRIs have to be considered, as SSRIs cross the placenta and are excreted into breast milk. The overall risk of major congenital malformations during SSRI exposure in the first trimester does not appear to be greatly increased. Depending on the variability in pharmacokinetic properties between the different SSRIs and the individual drug metabolism of mother and child, SSRI exposure during late pregnancy can lead to serotonin reuptake inhibitor-related symptoms in up to 30% of exposed infants postnatally. Symptoms are generally mild and self-limited, but need observation during at least 48 h as some infants develop severe symptoms needing intervention. Limited data are available about the long-term neurodevelopmental outcomes after SSRI exposure during pregnancy and lactation, but currently, cognitive development seems normal, while behavioural abnormalities may be increased.<\/jats:p>\n                  <jats:p>In this article, the available clinical data are reviewed. Additionally, the authors provide a multidisciplinary guideline for the monitoring and management of neonates exposed to SSRIs during pregnancy and lactation.<\/jats:p>","DOI":"10.1136\/archdischild-2011-214239","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T13:28:53Z","timestamp":1452173333000},"page":"F472-F476","source":"Crossref","is-referenced-by-count":69,"title":["Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation"],"prefix":"10.1136","volume":"97","author":[{"given":"S D","family":"Sie","sequence":"first","affiliation":[{"name":"Department of Neonatology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M B","family":"Wennink","sequence":"additional","affiliation":[{"name":"St. Lucas Andreas Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"van Driel","sequence":"additional","affiliation":[{"name":"St. Lucas Andreas Hospital, Amsterdam, The Netherlands"},{"name":"Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A G W","family":"te Winkel","sequence":"additional","affiliation":[{"name":"Teratology Information Service, Netherlands Pharmacovigilance Centre, \u2018s-Hertogenbosch, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Boer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynaecology, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Casteelen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"van Weissenbruch","sequence":"additional","affiliation":[{"name":"Department of Neonatology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,10,18]]},"reference":[{"key":"2025090512392267000_97.6.F472.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.23.3095"},{"key":"2025090512392267000_97.6.F472.2","first-page":"9","article-title":"Epidemiology of depression throughout the female life cycle","volume":"63","author":"Burt","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"2025090512392267000_97.6.F472.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000116689.75396.5f"},{"key":"2025090512392267000_97.6.F472.4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/070674370404901103","article-title":"Perinatal risks of untreated depression during pregnancy","volume":"49","author":"Bonari","year":"2004","journal-title":"Can J Psychiatry"},{"key":"2025090512392267000_97.6.F472.5","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000183597.31630.db"},{"key":"2025090512392267000_97.6.F472.6","doi-asserted-by":"publisher","DOI":"10.1089\/154099903765448880"},{"key":"2025090512392267000_97.6.F472.7","unstructured":"Marcus SM . Depression during pregnancy: rates, risks and consequences \u2013 Motherisk Update 2008. Can J Clin Pharmacol 2009;16:e15\u201322."},{"key":"2025090512392267000_97.6.F472.8","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00004"},{"key":"2025090512392267000_97.6.F472.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.5.499"},{"key":"2025090512392267000_97.6.F472.10","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.898"},{"key":"2025090512392267000_97.6.F472.11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06071172"},{"key":"2025090512392267000_97.6.F472.12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08081170"},{"key":"2025090512392267000_97.6.F472.13","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e3181b52da6"},{"key":"2025090512392267000_97.6.F472.14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdra.20641","article-title":"First-trimester use of paroxetine and congenital heart defects: a population-based case-control study","volume":"88","author":"Bakker","year":"2010","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"key":"2025090512392267000_97.6.F472.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0177-0"},{"key":"2025090512392267000_97.6.F472.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03048.x"},{"key":"2025090512392267000_97.6.F472.17","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181ba0632"},{"key":"2025090512392267000_97.6.F472.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00048-0"},{"key":"2025090512392267000_97.6.F472.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351402"},{"key":"2025090512392267000_97.6.F472.20","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050664"},{"key":"2025090512392267000_97.6.F472.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00070-7"},{"key":"2025090512392267000_97.6.F472.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.8.609"},{"key":"2025090512392267000_97.6.F472.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500170076037"},{"key":"2025090512392267000_97.6.F472.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2004.09.007"},{"key":"2025090512392267000_97.6.F472.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2005.11.006"},{"key":"2025090512392267000_97.6.F472.26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2008.03261.x","article-title":"Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study","volume":"66","author":"Diav-Citrin","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2025090512392267000_97.6.F472.27","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20327"},{"key":"2025090512392267000_97.6.F472.28","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291709992194"},{"key":"2025090512392267000_97.6.F472.29","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20099"},{"key":"2025090512392267000_97.6.F472.30","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1463"},{"key":"2025090512392267000_97.6.F472.31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07060879"},{"key":"2025090512392267000_97.6.F472.32","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000187302.61812.53"},{"key":"2025090512392267000_97.6.F472.33","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20144"},{"key":"2025090512392267000_97.6.F472.34","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000239581.76793.ae"},{"key":"2025090512392267000_97.6.F472.35","doi-asserted-by":"crossref","unstructured":"Pedersen LH Henriksen TB Vestergaard M . Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.","DOI":"10.1136\/bmj.b3569"},{"key":"2025090512392267000_97.6.F472.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066584"},{"key":"2025090512392267000_97.6.F472.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067407"},{"key":"2025090512392267000_97.6.F472.38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CLEP.S9256","article-title":"Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis","volume":"2","author":"Kornum","year":"2010","journal-title":"Clin Epidemiol"},{"key":"2025090512392267000_97.6.F472.39","unstructured":"GlaxoSmithKline . Bupropion and Paroxetine (Study No. EPIP083). GlaxoSmithKline, UK, 2005."},{"key":"2025090512392267000_97.6.F472.40","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0817"},{"key":"2025090512392267000_97.6.F472.41","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.10.1728"},{"key":"2025090512392267000_97.6.F472.42","doi-asserted-by":"publisher","DOI":"10.4065\/84.1.23"},{"key":"2025090512392267000_97.6.F472.43","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318173aa2e"},{"key":"2025090512392267000_97.6.F472.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.19.2372"},{"key":"2025090512392267000_97.6.F472.45","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0214"},{"key":"2025090512392267000_97.6.F472.46","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-45176"},{"key":"2025090512392267000_97.6.F472.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2006.00962.x"},{"key":"2025090512392267000_97.6.F472.48","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.160.2.173"},{"key":"2025090512392267000_97.6.F472.49","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.156.11.1129"},{"key":"2025090512392267000_97.6.F472.50","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.158.4.312"},{"key":"2025090512392267000_97.6.F472.51","unstructured":"Van Driel JJ Wennink JMB Heres MH . Intrauterine exposure to SSRIs: no reason for routine hypoglycaemia screening. Ned Tijdschr Geneeskd 2010;154:A339."},{"key":"2025090512392267000_97.6.F472.52","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2010.51"},{"key":"2025090512392267000_97.6.F472.53","first-page":"141","article-title":"Neonatal abstinence syndrome: assessment and management","volume":"2","author":"Finnegan","year":"1975","journal-title":"Addict Dis"},{"key":"2025090512392267000_97.6.F472.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052744"},{"key":"2025090512392267000_97.6.F472.55","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1710"},{"key":"2025090512392267000_97.6.F472.56","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-D\u00edaz S Van Marter LJ Werler MM . Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007;120:e272\u201382.","DOI":"10.1542\/peds.2006-3037"},{"key":"2025090512392267000_97.6.F472.57","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1262507"},{"key":"2025090512392267000_97.6.F472.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.07.009"},{"key":"2025090512392267000_97.6.F472.59","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519070-00004"},{"key":"2025090512392267000_97.6.F472.60","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.161.1.22"},{"key":"2025090512392267000_97.6.F472.61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/jp.2010.211","article-title":"Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome","volume":"31","author":"Klinger","year":"2011","journal-title":"J Perinatol"},{"key":"2025090512392267000_97.6.F472.62","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528020-00005"},{"key":"2025090512392267000_97.6.F472.63","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-007-0173-0"},{"key":"2025090512392267000_97.6.F472.64","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.1066"},{"key":"2025090512392267000_97.6.F472.65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211352"},{"key":"2025090512392267000_97.6.F472.66","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e3181b52bd6"},{"key":"2025090512392267000_97.6.F472.67","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730020-00002"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2011-214239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:39:32Z","timestamp":1757101172000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2011-214239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,18]]},"references-count":67,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,10,18]]},"published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1136\/archdischild-2011-214239"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2011-214239","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,18]]}}}